CEACAM5 and lung adenocarcinoma: 1999). Moreover, in our validation dataset, CEA exhibited the considerably high sensitivity of about 30% for early-stage lung adenocarcinoma (Fig. 4D), suggesting that our validation dataset could be biased due to small sample size described above.